Preparation, physicochemical characterization and cyctotoxicity of solid dispersion of paclitaxel and polyvinylpyrrolidone

Abstract

Abstract:

The objective of this study was to prepare and characterize paclitaxel-polyvinylpyrrolidone (PTX-PVP) solid dispersions with the intention of improving its solubility and dissolution properties. The PTX-PVP solid dispersion systems were prepared by solvent method. The release rate of paclitaxel was determined from dissolution studies and the physicochemical properties of solid dispersion were investigated by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and scanning electron microscopy (SEM). The cytotoxicities of paclitaxel in solid dispersion to the SKOV-3 cells were assayed by a SRB staining method. The results showed that the solubility and dissolution rate of paclitaxel were significantly improved in solid dispersion system compared with that of the pure drug and physical mixture. The results of DSC and PXRD showed that the paclitaxel in solid dispersion was amorphous form. No paclitaxel crystals in the solid dispersions was found during SEM analysis. Cytotoxicity study suggested that the inhibitory rates of PTX-PVP solid dispersion to SKOV-3 cells were higher than that of pure paclitaxel. The solubility and dissolution of paclitaxel were improved by solid dispersion technique. In vitro cytotoxicity of paclitaxel in solid dispersion was higher than that of pure drug.

Key words: Paclitaxel, Paclitaxel, Polyvinylpyrrolidone, Polyvinylpyrrolidone, Solid dispersion, Solid dispersion, Solubility, Solubility, Dissolution rate, Dissolution rate, Cytotoxicity assay, Cytotoxicity assay, ,

CLC Number:

R943

Supporting:

Jia-Bei Sun, Xiang-Rui Liu, Jian-Cheng Wang, Wan-Liang Lu, Xuan Zhang*,
Qiang Zhang.

Preparation, physicochemical characterization and cyctotoxicity of solid
dispersion of paclitaxel and polyvinylpyrrolidone

[J]. .

References

[1] Manfredi, J.J.; Horwitz, S.B. Pharmacol. Ther. 1984, 25, 83-125.
[2] Anon. Med. Lett. Drugs. Ther. 1993, 35, 39-40.
[3] Capri, G.; Tarenzi, E.; Fulfaro, F.; Gianni, L. Semin. Oncol. 1996, 23, 68-75.
[4] Szebeni, J.; Alving, C.R.; Savay, S.; Barenholz, Y.; Priev, A.; Danino, D.; Talmon, Y. Int. Immunopharmacol. 2001, 1, 721-735.
[5] Zhang, J.A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Eur. J. Pharm. Biopharm. 2005, 59, 177-187.
[6] Kim, J.H.; Kim, Y.S.; Kim, S.; Park, J.H.; Kim, K.; Choi, K.; Chung, H.; Jeong, S.Y.; Park, R.W.; Kim, I.S.; Kwon, I.C. J. Controlled. Release. 2006, 111, 228-234.
[7] Zhang, Z.; Feng, S.S. Biomaterials. 2006, 27, 262-270.
[8] Stevens, P.J.; Sekido, M.; Lee, R.J. Pharm. Res. 2004, 21, 2153-2157.
[9] Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sohma, Y.; Kimura, K.; Kiso, Y. J. Med. Chem. 2003, 46, 3782-3784.
[10] Kang, B.K.; Chon, S.K.; Kim, S.H.; Jeong, S.Y.; Kim, M.S.; Cho, S.H.; Lee, H.B.; Khang, G. Int. J. Pharm. 2004, 286, 147-156.
[11] Huh, K.M.; Lee, S.C.; Cho, Y.W.; Lee, J.; Jeong, J.H.; Park, K. J. Controlled. Release. 2005, 101, 59-68.
[12] Sheen, P.C.; Khetarpal, V.K.; Cariola, C.M.; Rowlings, C.E. Int. J. Pharm. 1995, 118, 221-227.
[13] Okonogi, S.; Oguchi, T.; Yonemochi, E.; Puttipipatkhachorn, S.; Yamamoto, K. Int. J. Pharm. 1997, 156, 175-180.
[14] Leuner, C.; Dressman, J. Eur. J. Pharm. Biopharm. 2000, 50, 47-60.
[15] Liu, X.R; Wu, K.C.; Zhang, C.H.; Zhang, X.; Zhang, Q. J. Chin. Pharm. Sci. 2007, 16, 101-104.
[16] Straub, J.A.; Chickering, D.E.; Lovely, J.C.; Zhang, H. Shah, B. Waud, W.R. Bernstein, H. Pharm. Res. 2005, 22, 347-355.
[17] Marin, M.T.; Margarit, M.V.; Salcedo, G.E. Farmaco. 2002, 57, 723-727.
[18] Merlin, J.L.; Barberi-Heyob, M.; Bachmann, N. Ann. Oncol. 2002, 13, 1743-1748.
[19] Cardellina, J.H. J. Liq. Chromatogr (USA). 1991, 14 , 659.
[20] Gubskaya. Drug. Dev. Ind. Pharm. 1995, 21, 1953-1964.
[21] Villiers, M.M.; Wurster, D.E.; Vanderwatt, J.G.; Ketkar, A. Int. J. Pharm. 1998, 163, 219-224.
[22] Verheyen, S.; Blaton, N.; Kinget, R.; Mooter, G.V. Int. J. Pharm. 2002, 249, 48-58.
[23] Craig, D.Q. Int. J. Pharm. 2002, 231, 131-144.